National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Magnesium aspartate dihydrate is indicated for the treatment and prevention of magnesium deficiency as diagnosed by a doctor. Magnaspartate is indicated in adults, children and adolescents aged from 2 years.


NCPE Assessment Process Complete
Rapid review commissioned 27/02/2019
Rapid review completed 14/05/2019
Rapid Review outcome A full HTA is not recommended. The NCPE recommends that magnesium aspartate dihydrate not be considered for reimbursement at the submitted price.  This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.